Zealand Pharma CEO to Discuss Metabolic Health Strategy at Goldman Sachs Conference
Event summary
- Zealand Pharma CEO Adam Steensberg to participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 9, 2026.
- Live audio webcast available at 1:20 PM EDT (7:20 PM CEST).
- Zealand Pharma focuses on obesity and metabolic health with 10 drug candidates in clinical development.
- Company has two marketed products and three late-stage candidates.
- Headquartered in Copenhagen, Denmark, with U.S. operations in Boston.
The big picture
Zealand Pharma's participation in the Goldman Sachs conference underscores its focus on metabolic health innovation. The company's proprietary data platform and AI/ML approaches position it as a key player in a rapidly evolving sector. With multiple drug candidates in development, Zealand Pharma aims to capitalize on the growing demand for obesity treatments, a market projected to reach significant scale in the coming years.
What we're watching
- Pipeline Progress
- How Zealand Pharma's late-stage candidates will advance its market position in obesity and metabolic health.
- Strategic Partnerships
- Whether collaborations with global pharmaceutical partners will accelerate commercialization efforts.
- Market Differentiation
- The pace at which Zealand Pharma can distinguish itself in a competitive metabolic health landscape.
Related topics